Skip to main content

Advertisement

SpringerLink
Log in

New Insights and Modern Treatment of AL Amyloidosis

  • Multiple Myeloma (R Niesvizky, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Systemic amyloidosis is a rare disease that is rarely cured. Systemic immunoglobulin light-chain amyloidosis (AL) is the most common type, usually the result of monoclonal light chains produced by a relatively indolent small plasma cell clone in the bone marrow. In AL, the direct toxicity of light chains, their misfolded intermediates, and deposition as amyloid fibrils in vital organs cause organ dysfunction and death. Often the diagnosis is delayed and the disease is advanced at presentation. Early diagnosis is possible with vigilance in clinical situations such as for patients with monoclonal gammopathy of undetermined significance who develop albuminuria or elevated cardiac biomarkers. Treatment is aimed at eradicating the clonal disease and restoring organ function; options include high dose melphalan followed by autologous stem cell transplantation, oral melphalan and dexamethasone, bortezomib-based combination chemotherapy and immunomodulatory agents such as lenalidomide or pomalidomide combined with dexamethasone. Cardiac involvement at baseline and the free light-chain hematologic response to therapy determine overall survival. Following measures of organ disease with cardiac and other biomarkers and of hematologic disease with serum free light chains is necessary to gauge organ and hematologic responses to therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Falk RH, Comenzo RL, Skinner M. The Systemic Amyloidoses. N Engl J Med. 1997;337:898–909.

    Article  PubMed  CAS  Google Scholar 

  2. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817–22.

    PubMed  CAS  Google Scholar 

  3. Pepys MB. Amyloidosis. Ann Rev med. 2006;57:223–42.

    Article  PubMed  CAS  Google Scholar 

  4. Comenzo RL. Current and emerging views and treatments of systemic immunoglobulin light-chain (AL) amyloidosis. Contrib Nephrol. 2007;153:195–210.

    Article  PubMed  CAS  Google Scholar 

  5. Brambilla F, Lavatelli F, Merlini G, Mauri P. Clinical proteomics for diagnosis and typing of systemic amyloidoses. Proteomics Clin Appl. 2013;7(1–2):136–43.

    Article  PubMed  CAS  Google Scholar 

  6. Comenzo RL, Zhou P, Fleisher M, Clark B, Teruya-Feldstein J. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood. 2006;107(9):3489–91.

    Article  PubMed  CAS  Google Scholar 

  7. Merlini G, Westermark P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Int Med. 2004;255:159–78.

    Article  CAS  Google Scholar 

  8. •• Comenzo RL. How I treat amyloidosis. Blood. 2009;114(15):3147–57. This is an excellent review for readers who want to grasp the fundamental basics of AL amyloidosis. Written in a case based format supported by in-depth and critical analysis of the literature in the field makes it a must read article by all who are interested in this disease.

    Article  PubMed  CAS  Google Scholar 

  9. Gertz MA, Kyle RA. Primary systemic smyloidosis-a diagnostic primer. Mayo Clin Proc. 1989;64(12):1505–19.

    Article  PubMed  CAS  Google Scholar 

  10. •• Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013 May 13. This is another must-read up-to-date review article likely to have wide spread reading and citations in the field of AL amyloidosis. The authors have done a commendable job in presenting the review concise yet complete for clinicians who diagnose and treat patients with AL amyloidosis.

  11. Comenzo RL. Managing systemic light-chain amyloidosis. J Natl Compr Canc Netw. 2007;5(2):179–87.

    PubMed  CAS  Google Scholar 

  12. •• Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26(11):2317–25. This article will have far reaching influences because it provides the basis for design and conduct of future clinical trial and pharma-academia collaboration for innovative strategies to our fight against AL amyloidosis.

    Article  PubMed  CAS  Google Scholar 

  13. •• Vrana JA, Gamez JD, Madden BJ, Theis JD, 3rd Bergen HR, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957–9. Laser microdissection and mass spectrometry has revolutionized the accuracy of amyloid typing and helping clinicians and researchers to distinguish AL from non-AL amyloidosis.

    Article  PubMed  CAS  Google Scholar 

  14. Hoffman JE, Hassoun H, Landau H, Comenzo RL. Coincidental Gammopathies in Patients with Systemic Amyloidosis and Transthyretin Gene Mutations. ASH 2010 Poster 2948 (II-828)

  15. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751–7.

    Article  PubMed  CAS  Google Scholar 

  16. Katmann JA, Kyle RA, Benson J, et al. Screning panels for detection of monoclonal gammopathies. Clin Chem. 2009;55(8):1517–22.

    Article  Google Scholar 

  17. Kyle RA, Gertz MA. Primary Systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1):45–59.

    PubMed  CAS  Google Scholar 

  18. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122(1):78–84.

    Article  PubMed  CAS  Google Scholar 

  19. DA Palladini G, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, et al. Validation of the Criteria of Response to Treatment In AL Amyloidosis. Blood. 2010;116:1364a.

    Article  Google Scholar 

  20. Bochtler T, Hegenbart U, Benner A, KunzC, Hose D, Seckinger A et al. Prognostic significance of cytogenetic aberrations in light chain amyloidosis patients treated with melphalan / dexamethasone as first-line therapy. XIIIth International Symposium on Amyloidosis. Groningen, The Netherlands, May 6-10, 2012. Abstract 15.15 - OP 40, p 52.

  21. • Zhou P, Hoffman J, Landau H, Hassoun H, Iyer L, Comenzo RL. Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis. Clin Lymphoma Myeloma Leuk. 2012;12(1):49–58. Both references 21 and 22 are about the information in the genetics of clonal plasma cells in the outcome of patients with AL amyloidosis. The emphasis in the genetic information should be the part of work up in clinics and in the translational researches in AL.

    Article  PubMed  CAS  Google Scholar 

  22. • Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica. 2009;94(3):380–6. Both references 21 and 22 are about the information in the genetics of clonal plasma cells in the outcome of patients with AL amyloidosis. The emphasis in the genetic information should be the part of work up in clinics and in the translational researches in AL.

    Article  PubMed  CAS  Google Scholar 

  23. Trinkaus-Randall V, Walsh MT, Steeves S, Monis G, Connors LH, Skinner M. Cellular response of cardiac fibroblasts to amyloidogenic light chains. Am J Pahol. 2005;166(1):197–208.

    Article  CAS  Google Scholar 

  24. Palladini G, Comenzo RL. The challenge of systemic immunoglobulin light-chain amyloidosis (Al). Subcell Biochem. 2012;65:609–42.

    Article  PubMed  CAS  Google Scholar 

  25. Merlini G. CyBorD: stellar response rates in AL amyloidosis. Blood. 2012;119(19):4343–5.

    Article  PubMed  CAS  Google Scholar 

  26. Dubrey SW, Comenzo RL. Amyloid diseases of the heart: current and future therapies. QJM. 2012;105(7):617–31.

    Article  PubMed  CAS  Google Scholar 

  27. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420–7.

    Article  PubMed  CAS  Google Scholar 

  28. Dietrich S, Schönland SO, Benner A, Bochtler T, Kristen AV, Beimler J, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood. 2010;116(4):522–8.

    Article  PubMed  CAS  Google Scholar 

  29. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011;118(4):865–73.

    Article  PubMed  CAS  Google Scholar 

  30. Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica. 2007;92(10):1302–7.

    Article  PubMed  CAS  Google Scholar 

  31. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB. et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391–4.

    Article  PubMed  CAS  Google Scholar 

  32. Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387–90.

    Article  PubMed  CAS  Google Scholar 

  33. Shah GL, Kaul E, Fallo S, Cossor FI, Smith H, Klein AK, et al. Subcutaneous Bortezomib in Combination Regimens in Newly Diagnosed Patients with Myeloma or Systemic AL Amyloidosis: High Response Rates and Minimal Toxicity. Blood (ASH Annual Meeting Abstracts #2968). 2012;120(21):2968.

    Google Scholar 

  34. Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol. 2007;139(2):224–33.

    Article  PubMed  CAS  Google Scholar 

  35. Landau H, Hassoun H, Rosenzweig MA, Maurer M, Liu J, Flombaum C, et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia. 2013;27(4):823–8.

    Article  PubMed  CAS  Google Scholar 

  36. Landau H, Hassoun H, Bello C, Hoover E, Riedel ER, Nimer SD, et al. Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid. 2011;18 Suppl 1:135–6.

    Article  PubMed  Google Scholar 

  37. Comenzo RL, Fein DE, Hassoun H, et al. Long-term outcomes of patients with systemic light chain amyloidosis (AL) treated at diagnosis with risk-adapted stem cell transplant and consolidation with novel agents. Blood (ASH Annual Meeting Abstracts). 2012;120(21):3150.

    Google Scholar 

  38. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103(8):2936–8.

    Article  PubMed  CAS  Google Scholar 

  39. Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood. 2007;110(2):787–8.

    Article  PubMed  CAS  Google Scholar 

  40. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicines. N Engl J Med. 1997;336(17):1202–7.

    Article  PubMed  CAS  Google Scholar 

  41. Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. 1996;100(3):290–8.

    Article  PubMed  CAS  Google Scholar 

  42. Gertz MA, Kyle RA. Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Arch Intern Med. 1990;150(3):629–33.

    Article  PubMed  CAS  Google Scholar 

  43. A Trial for Systemic Light-chain (AL) Amyloidosis (EMN-03). ClinicalTrials.gov Identifier:NCT01078454

  44. Wechalekar AD, Goodman H, Lachmann H, Offer M, Hawkins P, Gillmore J. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109(2):457–64.

    Article  PubMed  CAS  Google Scholar 

  45. Palladini G, Russo P, Foli A, Milani P, Lavatelli F, Obici L, et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol. 2012;91(1):89–92.

    Article  PubMed  CAS  Google Scholar 

  46. Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012;119(23):5397–404.

    Article  PubMed  CAS  Google Scholar 

  47. Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031–7.

    Article  PubMed  CAS  Google Scholar 

  48. Lu J, Wang H, Huang XJ. Curative effect observation of patients with primary systemic amyloidosis treated by the combination of bortezomib with dexmethasone and cyclophosphamide. Zhonghua Xue Ye Xue Za Zhi. 2013;34(4):345–8. article in Chinese.

    PubMed  Google Scholar 

  49. A Safety Study of Carfilzomib in Patients with Previously-Treated Systemic Light Chain Amyloidosis. ClinicalTrials.gov Identifier:NCT01789242

  50. Study of Oral MLN9708 in Adult Patients with Relapsed or Refractory Light Chain Amyloidosis. ClinicalTrials.gov Identifier:NCT01318902

  51. Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis. ClinicalTrials.gov Identifier:NCT01659658

  52. Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients with Relapsed AL Amyloidosis. ClinicalTrials.gov Identifier:NCT01222260

  53. A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects with Previously-Treated AL Amyloidosis. ClinicalTrials.gov Identifier:NCT01570387

  54. Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis. ClinicalTrials.gov Identifier:NCT01510613

  55. Comenzo RL. Who knows how to treat systemic light chain amyloidosis? Oncology (Williston Park). 2011;25(7):626, 628–9, 632–3

  56. Suhr OB, Ericzon BG. Selection of hereditary transthyretin amyloid patients for liver transplantation: the Swedish experience. Amyloid. 2012;19 Suppl 1:78–80.

    Article  PubMed  Google Scholar 

  57. Coelho T, Maia LF. Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–92.

    Article  PubMed  CAS  Google Scholar 

  58. Dispenzieri A, Gertz MA, Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev. 2012;26(4):137–54.

    Article  PubMed  Google Scholar 

  59. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99(12):4276–82.

    Article  PubMed  CAS  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflicts of Interest

C. Chaulagain: none; R. Comenzo: consultant for Millenium Pharmaceuticals and Prothena Biotech.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Tufts Medical Center and Tufts University School of Medicine, 800 Washington Street, Boston, MA, 02111, USA

    Chakra P. Chaulagain & Raymond L. Comenzo

Authors
  1. Chakra P. Chaulagain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raymond L. Comenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chakra P. Chaulagain.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chaulagain, C.P., Comenzo, R.L. New Insights and Modern Treatment of AL Amyloidosis. Curr Hematol Malig Rep 8, 291–298 (2013). https://doi.org/10.1007/s11899-013-0175-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-013-0175-0

Keywords

Search

Navigation